Our Data

An ever-growing body of data

We partner with biopharma companies and academic institutions to continuously validate and optimize our ex vivo platform. These efforts include research collaborations and ongoing clinical trials. Here, we invite you to dive deeper into the data behind our platform.

Our research

Paper published in Journal of Biomedical Optics

Label-free fluorescence lifetime imaging for the assessment of cell viability in living tumor fragments

We have developed and fully characterized a label-free imaging assay of cell viability based on multiphoton fluorescence lifetime imaging microscopy that leaves tissues intact and viable for repeated assessment of specimens over time, as well as downstream evaluation with other Elephas platform assays.

Paper published in Biomedical Optics Express

Assessing cell viability with dynamic optical coherence microscopy

We demonstrate that dynamic optical coherence microscopy, a technical component of the Elephas platform, can distinguish live cells from dead cells in murine syngeneic tumors.

Poster presented at AACR 2024, San Diego

Assessing cytotoxic T cell responses to immune checkpoint inhibitors in murine and human tumor samples using metabolic imaging

The Elephas platform can be used to assess immune checkpoint inhibitor response in clinically relevant core needle biopsies.

Poster presented at SITC 2023, San Diego

Assessing cytotoxic T cell responses in live tumor fragments with multiphoton microscopy

The Elephas platform can simultaneously assess activation of T cells and cytotoxic killing of tumor cells in response to immune checkpoint inhibitors.

Poster presented at AACR 2023, Orlando

Label-free imaging for rapid assessment of tumor viability in live tumor fragments

Using nondestructive, label-free multiphoton microscopy, the Elephas platform accurately predicts live/dead status of live tumor fragments (LTFs) and can assess tumors longitudinally.

Poster presented at SITC 2022, Boston

Murine live tumor fragments can be used to assess immunotherapy response

The Elephas platform addresses heterogeneity of tumors and creates homogenous treatment groups which can receive adoptive T cells, indicating CAR T-cell therapy can be assessed on the platform.

Poster presented at AACR 2022, New Orleans

A live tumor fragment platform with imaging for immune response assays

LTFs are viable, maintain motility of T cells and respond to checkpoint inhibitors by increasing cell surface marker expression and cytokine production, supporting the maintenance of the tumor microenvironment in our platform.

Poster presented at AACR 2022, New Orleans

Tumor/normal and live/dead classification in live tumor fragments using label-free multiphoton microscopy

The Elephas platform leverages nondestructive multiphoton label-free imaging to differentiate between live and dead cells in LTFs.

Poster presented at AACR 2022, New Orleans

Dynamic imaging of T cell surveillance in live tumor fragments using camelid nanobodies

The Elephas platform can track the motility of T cells and can distinguish T cells from tumor associated macrophages.

Our Clinical Trials

In three observational clinical trials, we are analyzing patient biopsies on our platform to predict whether patients will respond to immunotherapy.

CYBRID-01 Lung Trial

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

CYBRID-02 Basket Trial in collaboration with Hoosier Cancer Research Network

Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Mayo Clinic Logo-1

CYBRID-04 Mayo Clinic

Mayo Clinic MC230901: Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

These trials will provide an opportunity to demonstrate correlation between ex vivo and clinical response to immunotherapy regimen.

We are assessing our platform in multiple solid tumor types

lungs

NON-SMALL CELL LUNG CANCER

ICN_Head-Neck_Cell

HEAD & NECK CANCER

skin

MELANOMA

bladder

BLADDER
CANCER

kidneys

KIDNEY
CANCER

ICM_Colon

COLORECTAL
CANCER

ICN_uterus

ENDOMETRIAL
CANCER

breast

TRIPLE NEGATIVE BREAST CANCER

liver

LIVER
CANCER

Primary endpoint: Sensitivity in predicting clinical response to immunotherapy

We are enrolling over 600 patients in our studies.

Hospitals and academic research centers within the US and Canada provide consented patient specimens.

If you are a physician, consider your patients for these trials.

If you are a patient, ask your doctor whether you may be eligible for one of our clinical trials.

ICN_Clinical_Diagnostics

Clinical Diagnostic

Learn how we're revolutionizing immunotherapy response prediction.

ICN_megaphone

Latest news

Stay up to date on our technology and services.